Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mette Stie has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bridging the Communication Gap on Complementary and Alternative Medicine in Prostate Cancer Care: A Scoping Review of Interventions

    by Astrid Næraa Høeg Vendelsøe, Trine Stub, Miek Jong, Louise Faurholt Øbro, Knud Ryom, Helene Jung, Mette Stie

  • Open Access

    Patients’ experiences with nursing care undergoing open abdominal aortic aneurysm repair: A qualitative systematic review and meta-synthesis

    by Sabine Heesemann, Mette Stie, Bodil Bjørnshave Noe, Trine Mejnert Jørgensen, Lisbeth Uhrenfeldt


  • Open Access

    Exploring family health, support, self-efficacy and quality of life during the cancer trajectory: a protocol for a longitudinal mixed methods multi-centre cohort study

    by Lærke K Tolstrup, Nana Hyldig, Soren Moller, Mette Stie, Mette Kjerholt, Mary Jarden, Karin Piil, Elisabeth Coyne, Cristina Garcia-Vivar, Barbara Voltelen, et al.

    Introduction A cancer diagnosis not only profoundly impacts individuals but also the very core of their families, reshaping their lives in many ways. However, there is a lack of focus on the well-being and health of the entire family across adult cancer research. This is concerning given that one-third of the Danish population will get a cancer diagnosis before the age of 75, suggesting that many Danes will become caregivers during their lifetime. In addition, identifying vulnerable families is challenging, and the determinant factors for their vulnerability are unknown. Aims The principal aim of this study is to investigate family health during cancer treatment. This will be done by gathering information on various parameters such as perceived support, quality of life and self-efficacy in patients with cancer and families across the cancer trajectory. Additionally, the study seeks to pinpoint particularly vulnerable families and investigate contributing factors to their vulnerability. Methods and analysis This mixed-methods study follows a sequential explanatory design, combining patient-reported outcomes in a longitudinal, prospective multicentre survey with interviews conducted with a nested sampling of the participants from the survey. A total of 240 patients diagnosed with prostate-, breast-, gastrointestinal- and lymphoma cancer, and designated adult family caregivers will be recruited from six different sites for the survey. Variables such as family health, needs and perceived support, quality of life, self-efficacy, depression, stress and resilience will be explored. Survey data will be collected at baseline, 3, 6, 12 and 18 months. The interviews (n=12–15) will be conducted twice with patients and caregivers jointly: once during the treatment phase (3 months) and once after completion of treatment (12 months). For the survey part, we estimated a sample size with 90% power and 5% significance to detect a minimal clinically important change in the Family Health Scale. Assuming an SD of √2×22 = 31, based on a cross-sectional SD of 22, 44 patients per group were required; to allow for dropout, 60 per group (240 total) were included. Patient and caregiver characteristics will be summarised descriptively. Longitudinal patient-reported outcomes will be analysed with linear mixed regression, separately for patients and caregivers. Changes will be reported as mean differences with 95% CIs and compared with published minimal clinically important differences or, if unavailable, 0.3×baseline SD. For the qualitative part, thematic analysis by Braun and Clarke is chosen to extract data, identify patterns and analyse data and themes from the interviews. NVivo will be used for coding interview data. Ethics and dissemination The study will be conducted in accordance with the Helsinki Declaration. Measures will be taken to ensure confidentiality, data protection and participant safety throughout the study. The results will be published in peer-reviewed journals and conference presentations. Trial registration number ClinicalTrials.gov: NCT06433349. Protocol version 2.0, June 2024.


  • Open Access

    CAMONCO 2: Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life

    by Mette Stie, Signe Timm, Charlotte Delmar, Birgitte Nørgaard, Lars Henrik Jensen

    The rising prevalence of complementary alternative medicine (CAM), including for example, dietary supplements, massage, and acupuncture, among patients with cancer underscores the necessity of integrating open dialogue about complementary alternative medicine (OD-CAM) into oncology treatment and care. PURPOSE: This randomized controlled trial aimed to investigate the impact of OD-CAM on patients' quality of life (QoL), emotional well-being, decision regret, and survival. Patients undergoing antineoplastic treatment were randomly allocated to receive standard care (SC) plus OD-CAM or SC alone. The primary end point was patient-reported QoL 8 weeks after enrollment. Secondary end points included patient-reported QoL, anxiety, depression, and decision regret at 12 and 24 weeks after enrollment and overall survival at 52 weeks after enrollment. MATERIALS AND METHODS: Patient-reported outcomes were evaluated using the European Organisation for Research and Treatment of Cancer Computer Adaptive Test Core questionnaire, the Hospital Anxiety and Depression questionnaire, and the Decision Regret Scale. RESULTS: A total of 210 patients were equally randomly assigned, leaving 105 patients in each group. No significant differences were observed in QoL, well-being, decision regret, or survival between the groups. CONCLUSION: OD-CAM did not demonstrate superiority over SC in enhancing the QoL and well-being of patients undergoing antineoplastic treatment. Increased levels of anxiety and fatigue might result from OD-CAM, underscoring the importance of the person-oriented approach inherent in OD-CAM. OD-CAM may hold clinical significance, especially for those already inclined toward CAM; however, further investigation into the essential components of OD-CAM and the characteristics of patients who are most likely to experience significant improvements of OD-CAM is recommended.


  • Open Access

    Clinical Practice Based on Theory: Reflections on Mudd et al.'s Review for Excellence in Nursing

    by Lisbeth Uhrenfeldt, Kathleen Galvin, Marianne Dyrby Lorenzen, Bente Martinsen, Mette Stie


  • Kan mundskyl med hvid te forebygge oral mucositis hos patienter med brystkræft?

    by Agnete Kaltoft, Anne Meyling Godskesen, Signe Timm, Cathrine Lundgaard Riis, Mette Stie

    Mundgener er en kendt bivirkning til kemoterapi med beskadigelse af mundslimhinden. Oral mucositis kan blandt andet forårsage øm mund...

  • Excellent Sygepleje som tænkehorisont - -en nødvendig ramme der bidrager til patienter og pårørendes oplevelse af velvære

    by Mette Stie, Dorthe Kronborg, Anette Sørensen Nissen, Christina Nielsen Bræmer, Lisbeth Uhrenfeldt

    Sygehus Lillebælt har gennem flere år arbejdet med at udvikle og integrere ’Excellent Sygepleje som tænkehorisont’. Arbejdet har afsæt dels i en analyse af begrebet excellent sygepleje, dels i en ambition om at præcisere sygeplejens selvstændige bidrag i patientens behandling og pleje og dels i et mål om at skabe et fælles fundament for sygepleje på Sygehus Lillebælt. ’Excellent Sygepleje som tænkehorisont’ indeholder i alt syv kernebegreber, som tilsammen definerer og beskriver forudsætninger og egenskaber ved excellent sygepleje, herunder at patientens oplevelse af velvære er en egenskab og, at høj faglighed, en tillidsfuld relation, personcentreret og etisk praksis samt nærvær er forudsætninger for udøvelse af excellent sygepleje. Excellent sygepleje er således en måde at være, tænke, reflektere, udøve og organisere sygepleje på. Tænkehorisonten understøttes af udvalgte sygeplejefaglige teorier og ambitionen er, at tænkehorisonten skal udgøre det fælles fundament for sygeplejen på Sygehus Lillebælt. Det fordrer ledelsesmæssig prioritering og organisering samt flere forskelligartede indsatser på tværs af sygehuset. Artiklen præsenterer baggrunden for arbejdet med excellent sygepleje, tænkehorisontens tilblivelse, indsatser der har til formål at integrere tænkehorisonten, erfaringer samt fremtidige perspektiver for udvikling og forskning i Excellent Sygepleje.


  • Patientperspektiver på livet med kræft -en drivkraft for Excellent Sygepleje

    by Ninna Vemmelund, Annegrete Thomsen, Rikke Johansen, Mette Stie

    Baggrund Flere mennesker lever med kræft, og mange oplever, at sygdom og behandling påvirker deres livskvalitet og velvære. På Onkologisk Afdeling, Sygehus Lillebælt, er ambitionen at tilbyde Excellent Sygepleje, der fremmer velvære ud fra patientens perspektiv. Formål At undersøge, hvad patienter oplever som livskvalitet og velvære i livet med kræft, med henblik på at udvikle sygeplejen. Metode Et kvalitativ interviewstudie med fænomenologisk-hermeneutisk tilgang er gennemført med 15 patienter i forskellige stadier af deres kræftforløb. Data er analyseret med tematisk meningsfortolkning. Resultater Tre gennemgående temaer blev identificeret: 1. Et godt hverdagsliv 2. Betydningsfulde relationer 3. Et forandret selvbillede. Temaerne påvirker hinanden og udgør kernen i patienternes oplevelse af livskvalitet og velvære. Konklusion Sygepleje, der understøtter patientens hverdagsliv, relationer og identitet, fremmer velvære og livskvalitet. Excellent Sygepleje tager afsæt i det, der er meningsfuldt for den enkelte patient.

  • Open Access

    Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial

    by Mette Stie, Charlotte Delmar, Birgitte Nørgaard, Lars Henrik Jensen

    Introduction Complementary and alternative medicine (CAM) has been shown to reduce symptoms and adverse effects and improve quality of life of patients undergoing conventional oncology treatment, but CAM might also cause symptoms and adverse effects such as headache and fatigue. Thus, patients need guidance towards safe and healthy use of CAM. According to published results, open dialogue about CAM (OD-CAM) between health professionals and patients as an integral part of anticancer treatment may improve patients’ quality of life and well-being. Since the literature on the issue is sparse, the aim of this study is to assess the efficacy of OD-CAM integrated early in conventional oncology treatment versus standard care (SC) in patients undergoing standard anticancer treatment. Methods and analysis The study is a randomised controlled trial, being conducted at an oncology outpatient clinic in Denmark. 207 patients undergoing curative or palliative oncology treatment for breast, gynaecological, prostate, pulmonary, colorectal, anal or pancreatic cancer will be randomly assigned to SC with or without OD-CAM. A nurse specialist will facilitate the OD-CAM in one or two sessions. The primary endpoint is patient reported quality of life in relation to psychological well-being 8 weeks after enrollment. Secondary endpoints are patient reported level of depression and anxiety, top concerns, and decision regret 8, 12 and 24 weeks after enrolment, and overall survival. Ethics and dissemination According to the Committee on Health Research Ethics for Southern Denmark, ethics approval of this study is not required (S-20202000-5, 20/1019). The Region of Southern Denmark (Journal no. 20/11100) approved the storing and handling of data. Participants’ informed consent will be obtained before inclusion and randomisation. The results of the study, whether positive, negative or inconclusive, will be disseminated through open-access, peer-reviewed publications, stake-holder-reporting and presentations at relevant conferences. Trial registration number NCT04299451.